Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis

Area of Science:

• Neuroscience
• Infectious Diseases
• Pharmacology

Background:

• Bacterial meningitis causes inflammation, leading to hearing loss, brain injury, and death.
• Matrix metalloproteinases (MMPs) and tumor necrosis factor alpha-converting enzyme (TACE) are key inflammatory mediators in meningitis.
• Doxycycline is an antibiotic with known anti-inflammatory properties.

Purpose of the Study:

• To investigate the therapeutic potential of doxycycline as an adjuvant therapy for bacterial meningitis.
• To evaluate the effects of doxycycline on inflammation, blood-brain barrier disruption, brain injury, and hearing loss in a preclinical model.

Main Methods:

• In vitro inhibition of TACE by doxycycline was assessed.
• In vivo effects of doxycycline on tumor necrosis factor alpha (TNF-α) levels in cerebrospinal fluid were measured.
• An infant rat model of pneumococcal meningitis was used to evaluate doxycycline's efficacy as adjuvant therapy with ceftriaxone.
• Auditory brainstem response audiometry was used to assess hearing loss.

Main Results:

• Doxycycline inhibited TACE in vitro and significantly reduced TNF-α release in vivo.
• Adjuvant doxycycline therapy reduced mortality, blood-brain barrier disruption, and cortical brain injury in infant rats.
• Doxycycline treatment attenuated hearing loss and neuronal death in the cochlear spiral ganglion.

Conclusions:

• Doxycycline exhibits broad beneficial effects in the brain and cochlea during bacterial meningitis.
• Its anti-inflammatory properties contribute to improved survival and reduced neurological and auditory damage.
• Doxycycline shows promise as an adjuvant therapy for bacterial meningitis.